iSpecimen stock: Third-quarter revenue rises 129%
Published on 11/19/2026 at 03:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly results and business outlook
- iSpecimen reported higher quarterly revenue and a narrower net loss for the period ended September 30.
- Cash stood at USD 5.56 million, while management continued to cite substantial doubt about the company continuing as a going concern.
- The company is expanding its biospecimen marketplace with AI tools for protein discovery and disease trend monitoring.
iSpecimen reported third-quarter revenue of USD 244,034 for the period ended September 30, 2026, compared with USD 106,592 a year earlier. The company filed its quarterly report with the Securities and Exchange Commission on November 17.
Operating expenses fell to USD 2.44 million from USD 2.94 million in the year-earlier quarter. The operating loss narrowed to USD 2.20 million from USD 2.83 million, while the net loss narrowed to USD 2.21 million from USD 2.78 million. Basic and diluted loss per share was USD 1.03, compared with USD 19.05 in the prior-year period, with both figures reported as losses.
Cash position remains central
Cash and cash equivalents totaled USD 5.56 million at September 30, down from USD 6.88 million at the end of 2025. iSpecimen used USD 6.75 million in operating activities during the first nine months of 2026 and reported positive working capital of USD 870,936.
Management said the financial statements raise substantial doubt about the company’s ability to continue as a going concern for one year from issuance. The filing says the company plans to increase revenue, defer selected projects and capital expenditures, and eliminate future operating costs, while noting that these measures may not succeed.
Marketplace gains AI extension
iSpecimen operates an online marketplace that connects medical researchers seeking human biospecimens and related data with hospitals, laboratories and other providers. The company is headquartered in Woburn, Massachusetts, and its principal market is North America, according to the filing and the company investor overview.
Its model differs from direct-supply and service providers such as BioIVT and Discovery Life Sciences, which offer biospecimens alongside research or laboratory services. iSpecimen focuses on coordinating access through a technology marketplace and provider network. The company also completed the acquisition of Foldlab AI products on November 2, expanding into protein discovery and disease trend monitoring.
iSpecimen company facts
- Company: iSpecimen Inc.
- ISIN: US45032V3069
- Ticker: ISPC
- Exchange: The Nasdaq Stock Market LLC
- Reporting period: Quarter ended September 30, 2026
- Revenue: USD 244,034
- Net loss: USD 2.21 million
- Cash and cash equivalents: USD 5.56 million at September 30, 2026
- Headquarters: Woburn, Massachusetts
US-listed shares remain tied to the broader US market environment; follow the S&P 500 for the wider backdrop.
More news and analyses on iSpecimen stock are available here.
